Events

EIT Digital: Grow Digital 23 Conference
JUN
Tue
06
JUN
Wed
07

This was 2 years ago

Location

Brussels

The EGG - Barastraat 175, 1070 Brussels
Programmes
Digital, Industry & Space EIT Digital Europe

EIT Digital organises the Grow Digital 23 Conference to bring together stakeholders from industry, research and academia to discuss the latest about digital innovation, discover ground breaking deep tech solutions, and make new connections.

Topics that will be discussed during the conference comprise

  • How can Europe ensure access to semi-conductors and enhance tech sovereignty?
  • How will Generative AI impact business and labour markets?
  • Which investments are needed to improve Europe’s Digital Security, step up in Space Tech, stay ahead of the curve in Industry 5.0, and ensure sufficient investment in talent and tech ventures?

For more information on the event, the agenda and the possibility to register please visit the event website.

Please note that this is a paying event. Early bird fees apply until 16 April 2023.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.